- Home
- LSBK vs GNLX Comparison
LSBK vs GNLX Comparison
Compare LSBK & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- GNLX
- Stock Information
- Founded
- LSBK 1891
- GNLX 2001
- Country
- LSBK United States
- GNLX United States
- Employees
- LSBK N/A
- GNLX N/A
- Industry
- LSBK Savings Institutions
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- GNLX Health Care
- Exchange
- LSBK Nasdaq
- GNLX Nasdaq
- Market Cap
- LSBK 90.0M
- GNLX 96.6M
- IPO Year
- LSBK 2006
- GNLX 2023
- Fundamental
- Price
- LSBK $15.93
- GNLX $2.83
- Analyst Decision
- LSBK
- GNLX Strong Buy
- Analyst Count
- LSBK 0
- GNLX 4
- Target Price
- LSBK N/A
- GNLX $17.75
- AVG Volume (30 Days)
- LSBK 3.2K
- GNLX 145.0K
- Earning Date
- LSBK 07-23-2025
- GNLX 08-13-2025
- Dividend Yield
- LSBK 3.38%
- GNLX N/A
- EPS Growth
- LSBK 27.62
- GNLX N/A
- EPS
- LSBK 0.89
- GNLX N/A
- Revenue
- LSBK $25,795,000.00
- GNLX N/A
- Revenue This Year
- LSBK N/A
- GNLX N/A
- Revenue Next Year
- LSBK N/A
- GNLX N/A
- P/E Ratio
- LSBK $17.70
- GNLX N/A
- Revenue Growth
- LSBK N/A
- GNLX N/A
- 52 Week Low
- LSBK $11.80
- GNLX $1.60
- 52 Week High
- LSBK $16.95
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- LSBK 65.17
- GNLX 54.19
- Support Level
- LSBK $15.68
- GNLX $2.87
- Resistance Level
- LSBK $15.73
- GNLX $3.17
- Average True Range (ATR)
- LSBK 0.07
- GNLX 0.24
- MACD
- LSBK -0.01
- GNLX 0.01
- Stochastic Oscillator
- LSBK 80.00
- GNLX 51.97
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.